Investment Research Partners LLC Takes $928,000 Position in Gilead Sciences, Inc. $GILD

Investment Research Partners LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 7,833 shares of the biopharmaceutical company’s stock, valued at approximately $928,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Gilead Sciences in the 2nd quarter valued at about $2,150,268,000. Ameriprise Financial Inc. grew its stake in shares of Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after acquiring an additional 5,392,191 shares in the last quarter. Invesco Ltd. increased its position in shares of Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after acquiring an additional 3,394,330 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Gilead Sciences by 164.4% in the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after acquiring an additional 2,169,266 shares in the last quarter. Finally, First Trust Advisors LP lifted its stake in shares of Gilead Sciences by 154.3% in the third quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after acquiring an additional 1,874,508 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 2.2%

Shares of NASDAQ GILD opened at $141.29 on Thursday. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The stock’s 50 day moving average price is $141.96 and its two-hundred day moving average price is $127.51. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The stock has a market capitalization of $175.40 billion, a P/E ratio of 20.87, a PEG ratio of 1.89 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter last year, the firm earned $1.90 EPS. The business’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Quarterly beat, raised guidance and dividend increase provide fundamental support — Gilead reported $1.86 EPS (vs. $1.83 est.), $7.93B revenue (vs. $7.68B est.), set FY‑2026 EPS guidance of $8.45–$8.85 and raised the quarterly dividend to $0.82. Those elements support longer‑term upside.
• Positive Sentiment: M&A/sector takeover chatter (Arcellx coverage) is reviving speculation that Gilead may pursue deals to bolster its cell‑therapy/oncology pipeline — a catalyst investors treat as strategic upside. Fool: Arcellx / takeover-related coverage
• Neutral Sentiment: Unusual options activity flagged by scanners — heightened option flow can signal hedging or speculative bets; it’s ambiguous until directional put/call skew and volume patterns solidify. Barchart: options activity
• Neutral Sentiment: Analysts show mixed/contrasting views — some firms have raised targets and reiterated buys while others are more cautious, so research flow is creating both support and headlines that can move sentiment. Globe and Mail: analysts conflicting
• Neutral Sentiment: New coverage of potential CAR‑T competitors (Estrella/ESLA) is worth watching but is not an immediate direct threat to Gilead’s larger, diversified franchise — more a sector development. Yahoo: ESLA coverage
• Negative Sentiment: Insider selling by senior executives — Johanna Mercier and CFO Andrew D. Dickinson each sold 3,000 shares (average ~$144.23) recently; multiple insider sales can sour near‑term sentiment even if part of planned diversification. InsiderTrades: insider sales
• Negative Sentiment: Recent headlines and retail coverage are bearish — pieces arguing to “avoid GILD” are amplifying outflows/weakness among some investors and may pressure the intraday move. Yahoo: 3 Reasons to Avoid GILD
• Negative Sentiment: Market‑coverage note reporting Gilead fell more than the broader market today — a short‑term confirmation of downward price pressure that may trigger additional technical selling. Zacks: GILD falls more than market

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the transaction, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at approximately $25,844,717.93. The trade was a 1.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the insider directly owned 131,779 shares of the company’s stock, valued at approximately $19,006,485.17. This represents a 2.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 309,280 shares of company stock worth $44,068,850 in the last ninety days. 0.27% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research note on Monday, February 23rd. Bank of America set a $162.00 target price on Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, February 11th. Truist Financial increased their target price on Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Sanford C. Bernstein reissued an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a research report on Wednesday, February 11th. Finally, Barclays started coverage on shares of Gilead Sciences in a research note on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price target for the company. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $157.62.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.